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Abstract
Introduction: Anemia is associated with poor outcomes in patients with aneurysmal subarachnoid hemorrhage
(SAH). It remains unclear whether this association can be modified with more aggressive use of red blood cell
(RBC) transfusions. The degree to which restrictive thresholds have been adopted in neurocritical care patients
remains unknown.
Methods: We performed a survey of North American academic neurointensivists, vascular neurosurgeons and
multidisciplinary intensivists who regularly care for patients with SAH to determine hemoglobin (Hb)
concentrations which commonly trigger a decision to initiate transfusion. We also assessed minimum and
maximum acceptable Hb goals in the context of a clinical trial and how decision-making is influenced by
advanced neurological monitoring, clinician characteristics and patient-specific factors.
Results: The survey was sent to 531 clinicians, of whom 282 (53%) responded. In a hypothetical patient with high-
grade SAH (WFNS 4), the mean Hb concentration at which clinicians administered RBCs was 8.19 g/dL (95% CI,
8.07 to 8.30 g/dL). Transfusion practices were comparatively more restrictive in patients with low-grade SAH (mean
Hb 7.85 g/dL (95% CI, 7.73 to 7.97 g/dL)) (P < 0.0001) and more liberal in patients with delayed cerebral ischemia
(DCI) (mean Hb 8.58 g/dL (95% CI, 8.45 to 8.72 g/dL)) (P < 0.0001). In each setting, there was a broad range of
opinions. The majority of respondents expressed a willingness to study a restrictive threshold of ≤8 g/dL (92%)
and a liberal goal of ≥10 g/dl (75%); in both cases, the preferred transfusion thresholds were significantly higher
for patients with DCI (P < 0.0001). Neurosurgeons expressed higher minimum Hb goals than intensivists, especially
for patients with high-grade SAH (b = 0.46, P = 0.003), and were more likely to administer two rather than one
unit of RBCs (56% vs. 19%; P < 0.0001). Institutional use of transfusion protocols was associated with more
restrictive practices. More senior clinicians preferred higher Hb goals in the context of a clinical trial. Respondents
were more likely to transfuse patients with brain tissue oxygen tension values <15 mmHg and lactate-to-pyruvate
ratios >40.
Conclusions: There is widespread variation in the use of RBC transfusions in SAH patients. Practices are heavily
influenced by the specific dynamic clinical characteristics of patients and may be further modified by clinician
specialty and seniority, the use of protocols and advanced neurological monitoring.
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The prevention of secondary brain injury is a key para-
digm of neurocritical care [1]. Inadequate cerebral oxy-
gen delivery is an important mechanism that may
contribute to secondary brain injury. This is particularly
true for patients with aneurysmal subarachnoid hemor-
rhage (SAH), where delayed cerebral ischemia (DCI)
and infarction frequently contribute to poor outcomes.
When carefully sought, angiographic vasospasm can be
observed in about two-thirds of patients during the 2
weeks after aneurysm rupture [2]. Among patients who
survive, evidence of acute infarction can be detected in
more than 50% of patients with the use of magnetic
resonance imaging [3]. In contrast to other neurocritical
care conditions, the high risk of delayed ischemia after
admission to the hospital provides a unique opportunity
to provide neuroprotection prior to additional insults.
Because the concentration of hemoglobin (Hb) is a
major determinant of arterial oxygen content, there is a
strong therapeutic rationale for the avoidance of anemia
in patients with brain injury [4]. Physiological studies
have demonstrated improvements in cerebral oxygena-
tion when red blood cell (RBC) transfusions are used to
raise Hb levels in anemic SAH patients, particularly
when oxygen delivery and cerebral perfusion are
reduced [4-7]. Several observational studies have found
an association between lower Hb concentrations and
poor outcomes [8-10]. Although the correction of ane-
mia is straightforward, the use of allogeneic RBC trans-
fusions to do so has potentially deleterious implications.
For example, associations with acute lung injury and
nosocomial infections have been described, which could
neutralize any physiological advantage [11-13].
Large, multicenter, randomized, controlled trials invol-
ving heterogeneous critically ill patients have not found
any benefit to the liberal use of RBC transfusions to
maintain higher Hb concentrations (>9 to 10 g/dL);
however, neurocritical care patients composed only a
small subset of the total patient population [14,15]. It is
currently unknown to what extent restrictive transfusion
thresholds (for example, <7 g/dL) have been adopted in
brain-injured patients. A previous international survey
suggested that most intensivists still consider a hemato-
crit level of about 30% to be optimal in SAH patients.
However, it does not necessarily follow that clinicians
would transfuse liberally to achieve this goal [16].
Furthermore, there are no data indicating how transfu-
sion decisions are guided by multimodal neurological
monitoring, which demographic and clinical factors may
influence practices and how low (or high) clinicians
might allow transfusion thresholds to be in the context
of a clinical trial. In view of this uncertainty, we con-
ducted a cross-sectional survey of North American
clinicians involved in the decision to administer blood
transfusions in critically ill SAH patients.
Materials and methods
The survey was endorsed by the clinical trials committee
of the Neurocritical Care Society. Our sampling frame
consisted of neurointensivists, multidisciplinary intensi-
vists who regularly care for SAH patients, and vascular
neurosurgeons. We specifically targeted individuals who
work at academic institutions with neurocritical care fel-
lowships and/or neurosurgery residency training pro-
grams, since these clinicians are the most likely to
participate in future clinical trials.
As of March 2010, there were 42 U.S. centers with
neurocritical care fellowship programs accredited by the
United Council for Neurologic Subspecialties. Through
the Society of Neurological Surgeons, we obtained a list
of an additional 56 U.S. centers with neurosurgical resi-
dency training programs but no accredited neurocritical
care fellowship program. Through the Canadian Resi-
dency Matching Service website, we identified 12 pri-
marily English-speaking universities with neurosurgery
residency programs.
Program directors were contacted to obtain a list of
local intensivists and vascular neurosurgeons who care
for SAH patients. For centers from which we received
no response, we obtained the names and email
addresses of relevant individuals from the respective
programs’ websites.
The survey was self-administered by the respondents,
voluntary and submitted online using SurveyMonkey
[17]. Individuals were contacted by email, with three
subsequent reminders sent at approximately 1-week
intervals. No monetary or other incentive was offered
for questionnaire completion. Respondents had the
option of filling out the survey anonymously.
Survey development was initiated by two investigators
(AHK and PDL) on the basis of a PubMed and MED-
LINE review of relevant literature [4], with feedback
from other experts (MND, AMN and RLM). Themes
that were considered important to explore included the
following: (1) transfusion thresholds in both low-grade
SAH patients (minimal neurological deficits; defined in
this study as World Federation of Neurological Surgeons
(WFNS) grades 1 to 3) and high-grade SAH patients
(presence of stupor or coma; WFNS grade 4 or 5);
(2) transfusion thresholds among patients with moderate
to severe angiographic or transcranial Doppler (TCD)-
defined vasospasm, but no clear symptoms of DCI;
(3) transfusion thresholds among patients with angio-
graphic vasospasm and neurological deterioration (that
is, DCI); (4) willingness of clinicians to accept transfu-
sion thresholds above or below their usual practices in
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transfusion thresholds on the basis of information pro-
vided by multimodal neurological monitoring.
Most relevant information was collected by presenting
an interactive case of a typical patient with aneurysmal
SAH who becomes anemic (see appendices in Addi-
tional files 1 and 2). Item reduction was accomplished
by piloting the survey among three vascular neurosur-
geons and four neurointensivists to ensure that it could
be completed in approximately 5 minutes and that the
most important themes were considered. These preli-
minary responses were not included as part of the final
survey results.
Several subgroup analyses were planned ap r i o r ito
determine how transfusion practices might be modified
on the basis of the following factors: (1) geography
(United States vs. Canada), (2) base specialty (neurosurgery
vs. intensivists), (3) seniority (years in practice), (4) the
presence of an institutional transfusion protocol and
(5) the use of multimodal neurological monitoring
(defined as the use of at least one of the following: brain
tissue oxygen tension (PbtO2) probes, microdialysis cathe-
ters, jugular venous oximetry or continuous cerebral
blood flow (CBF) monitors).
Statistical analysis was performed using SAS version
9.1 software (SAS Inc., Cary, NC, USA) and MedCalc
version 11.3 software (MedCalc, Mariakerke, Belgium).
The normality of data was assessed using the Shapiro-
Wilk test. Between-group comparisons of continuous
data were performed using the Student’s t-test or the
Wilcoxon rank-sum test, depending on the distribu-
tion of data. Two-sample paired tests were used where
applicable. Clinicians’ transfusion thresholds in multi-
ple settings were compared using the Friedman test (a
nonparametric approach analogous to repeated mea-
sures analysis of variance), and adjustment for multiple
comparisons was made using the Bonferroni correc-
tion method. Categorical data were assessed using c
2
analysis or Fisher’s exact test as appropriate on the
basis of the number of responses per cell. Associations
between transfusion thresholds and clinician charac-
teristics were explored using generalized linear regres-
sion models (Proc GLM in SAS). Multivariable
analysis, including all of the variables from our sub-
group analysis, was performed using a backward elimi-
nation process whereby the least significant variables
were discarded one-by-one if P > 0.05. Models were
assessed for heteroscedasticity using White’st e s t ;i f
present, a heteroscedasticity-consistent standard error
was used. We also assessed interactions (effect mea-
sure modification) between variables and included the
relevant interaction terms in the initial multivariable
models if they were statistically significant (P < 0.05)
in univariate analysis.
Results
Demographics
T h es u r v e yw a ss e n tt o5 3 1i n d i v i d u a l s ,f r o ma m o n g
w h o m2 8 2( 5 3 % )r e s p o n d e d .T h er e s p o n s er a t ew a s
higher in Canada than in the United States (69% vs.
43%; P < 0.0001). There were notable cross-border
differences in the base specialties of respondents; the
majority in the United States were neurologists
(55%) and neurosurgeons (23%) compared with inter-
nists (37%) and anesthesiologists (27%) in Canada
(Table 1).
Transfusion thresholds in clinical practice
Transfusion thresholds differed significantly, depending
on the specific clinical characteristics of the patients
(Figure 1) (P < 0.001). In a hypothetical patient with
WFNS grade 4 SAH (Glasgow Coma Scale (GCS) score
of 9, without a focal neurological deficit) and the
Table 1 Characteristics of survey respondents from the
United States and Canada
a
United
States
(n = 143)
Canada
(n = 139)
Total
(n = 282)
P value
Base specialty, %
Neurology 55% 2% 29% <0.0001
Neurosurgery 23% 15% 19%
Anesthesiology 10% 27% 19%
Internal medicine 7% 37% 22%
Emergency medicine 4% 6% 5%
Surgery 1% 12% 6%
Years of experience, %
0-3 34% 17% 26% 0.04
4-7 15% 24% 20%
8-10 10% 14% 11%
11-15 22% 21% 21%
16-20 7% 10% 9%
>20 13% 14% 13%
Monitoring tools, %
CT angiography 91% 88% 90% 0.50
CT perfusion 69% 24% 46% <0.0001
Transcranial Doppler 89% 63% 76% <0.0001
PbtO2 probes 34% 6% 21% <0.0001
Microdialysis
catheters
8% 1% 4% 0.005
b
Continuous CBF
probes
14% 0 7% <0.0001
b
Jugular bulb
oximetry
13% 12% 13% 0.79
MRI perfusion 33% 17% 25% 0.002
None of above 3% 4% 3% 0.75
b
Use of institutional
transfusion protocol, %
55% 50% 52% 0.42
aCT, computed tomography; PbtO2, brain tissue oxygen tension; CBF, cerebral
blood flow; MRI, magnetic resonance imaging;
bFisher’s exact test.
Kramer et al. Critical Care 2011, 15:R30
http://ccforum.com/content/15/1/R30
Page 3 of 11development of anemia on the third day in the hospital,
the mean Hb concentration at which clinicians would
choose to administer RBCs was 8.19 g/dL (95% confi-
dence interval (95% CI), 8.07 to 8.30; medians and inter-
quartile ranges (IQRs) are presented in Figure 1).
However, opinions varied widely from as low as 7 g/dL
(26%) to as high as 10 g/dL (13%).
Transfusion practices were more restrictive in a
patient with WFNS grade 1 SAH (GCS score 15) (mean
H b ,7 . 8 5g / d L ;9 5 %C I ,7 . 7 3t o7 . 9 7( P <0 . 0 0 0 1c o m -
pared with grade 4 SAH)). In contrast, in a patient with
evidence of moderate to severe TCD vasospasm (middle
cerebral artery flow velocities 180 to 205 cm/second,
Lindegaard ratio 5 or 6) on the sixth day in the hospital,
without any coinciding neurological deterioration, the
mean transfusion threshold rose to 8.35 g/dL (95% CI,
8.22 to 8.48; P = 0.001 compared with the same patient
on day 3 without TCD vasospasm). When there were
both angiographic vasospasm and concomitant observa-
ble neurological deterioration (that is, DCI), the mean
threshold was even higher at 8.58 g/dL (95% CI, 8.45 to
8.72; P < 0.0001 compared with the same patient on day
6 with only TCD vasospasm). For each clinical scenario,
there was a wide range of responses (Figure 1).
For patients with Hb concentrations slightly below (<1
g/dL) clinicians’ usual transfusion threshold, most
respondents (74%) initially administered 1 U of RBCs,
while a minority (26%) routinely gave 2 U of RBCs. The
proportion that administered 2 U of RBCs was larger in
the United States than in Canada (34% vs. 17%; P =
0.002) and among neurosurgeons compared with inten-
sivists (56% vs. 19%; P < 0.0001).
Figure 1 Hemoglobin (Hb) concentrations at which clinicians transfuse patients with aneurysmal subarachnoid hemorrhage (SAH).
Boxplots demonstrate median and interquartile range. Circles represent “outside values” (± 1.5 times the interquartile range). Means and 95%
confidence intervals are presented in the Results section. DCI, delayed cerebral ischemia; grade refers to World Federation of Neurological
Surgeons classification for SAH. *P < 0.0001 in relation to grade 4 SAH (assessed using paired Wilcoxon rank-sum test and Bonferroni correction
for multiple comparisons). **P = 0.001 in relation to grade 4 SAH (assessed using paired Wilcoxon rank-sum test and Bonferroni correction for
multiple comparisons).
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I nt h ep a t i e n tw i t hg r a d e4S A H ,6 3 %o fr e s p o n d e n t s
expressed a willingness to accept a Hb threshold lower
than their own in a clinical trial. When clinicians with
the most restrictive threshold (7 g/dL) were excluded,
the proportion rose to 84%. More than 70% of respon-
dents thought it was ethically acceptable to randomize
patients to a transfusion trigger as low as 7 or 7.5 g/dL
(Figure 2A). Similarly, 94% of respondents were willing
to accept a Hb threshold higher than their own in a
study, in most cases ≥10 g/dL (Figure 2B).
Acceptable lower transfusion thresholds were influ-
enced by the presence or absence of DCI (mean accep-
table threshold with DCI, 7.69 g/dL (median, 7.5; IQR,
7.0 to 8.0); mean acceptable threshold without DCI, 7.41
g/dL (median, 7.0; IQR, 7.0 to 8.0); P < 0.0001). How-
ever, even in patients with DCI, 63% of respondents
expressed their willingness to study a Hb threshold
lower than their own (84% when those with a threshold
of 7 g/dL were excluded). More than half supported
allocating patients to a transfusion trigger of 7 or 7.5 g/dL
(Figure 2A). Ninety percent of respondents were willing to
study a Hb target higher than their own. The majority
favored an upper target of 10 g/dL, but a sizable propor-
tion were willing to increase transfusion to levels exceed-
ing 11 g/dL (Figure 2B). The mean upper acceptable Hb
target was greater in patients who develop DCI (mean,
10.31 g/dL (median, 10.0; IQR, 10.0 to 11.0) vs. mean
10.11 g/dL (median, 10.0; IQR, 10.0 to 10.5); P < 0.0001).
Clinician characteristics influencing transfusion practices:
subgroup analysis
U.S. clinicians consistently reported transfusing at
higher Hb concentrations than Canadian clinicians
(Figure 3A). However, this difference reached statistical
significance only for patients with DCI (mean Hb level
among U.S. clinicians, 8.74 g/dL (95% CI, 8.55 to 8.92);
mean Hb level among clinicians in Canada, 8.44 g/dL
(95% CI, 8.25 to 8.63); P = 0.03). There were no major
differences in the maximum and minimum Hb concen-
trations that clinicians from either country would con-
sider acceptable in a randomized, controlled trial
(Figure 4A).
Neurosurgeons reported more liberal transfusion
thresholds than did intensivists (Figure 3B). Differences
were statistically significant for patients with grade 4
SAH, grade 1 SAH and TCD vasospasm. Neurosurgeons
were also less willing than intensivists to accept very
low Hb concentrations (7 to 7.5 g/dL) in the setting of a
randomized, controlled trial and were more willing to
transfuse to relatively high Hb targets (10 to 11.5 g/dL)
(Figure 4B).
Clinicians who routinely use multimodal neurological
monitoring in SAH patients report targeting higher Hb
concentrations, especially in patients with DCI (mean
Hb with multimodal monitoring, 8.82 g/dL (95% CI,
8.55 to 0.10); mean Hb without monitoring, 8.50 g/dL
(95% CI, 8.35 to 8.66); P = 0.04) (Figure 3C). Appendix
2i nA d d i t i o n a lf i l e2s h o w ss p ecifically how the use of
PbtO2 and microdialysis monitoring may modify prac-
tices. The use of institutional transfusion protocols was
associated with more restrictive thresholds, especially in
grade 1 SAH patients (mean Hb with transfusion proto-
col, 7.70 g/dL (95% CI, 7.54 to 7.87); mean Hb without
protocol, 7.98 g/dL (95% CI, 7.80 to 8.16); P =0 . 0 1 )
(Figure 3D).
There were no significant associations between clini-
cian experience (years in practice) and conventional
Figure 2 Minimum and maximum hemoglobin (Hb) concentrations which clinicians consider acceptable thresholds for a randomized
trial. (A) Minimum acceptable transfusion threshold. (B) Maximum acceptable transfusion threshold. DCI, delayed cerebral ischemia. “Grade”
refers to World Federation of Neurological Surgeons classification.
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ever, more experienced respondents were less willing to
accept lower Hb thresholds in the restrictive arm of a
randomized, controlled trial (grade 4 SAH, b = 0.01, P =
0.009; DCI, b = 0.02, P = 0.01). In the liberal transfusion
group, more experienced respondents reported that they
would be willing to transfuse to higher Hb targets
(grade 4 SAH, b =0 . 0 2 ,P = 0.04; DCI, b =0 . 0 2 ,P =
0.01).
Clinician characteristics influencing transfusion practices:
multivariable analysis
Using multivariable analysis, several independent predic-
tors of transfusion practices were identified (Table 2).
Hemoglobin thresholds were more liberal among neuro-
surgeons than among intensivists (grade 4 SAH, b =
0.46, P = 0.003; TCD vasospasm, b =0 . 3 1 ,P = 0.04)
and more restrictive among clinicians who use transfu-
sion protocols (grade 1 SAH, b = -0.42, P = 0.0008). In
grade 1 SAH patients, we also found significant effect
measure modification between the use of a protocol and
neurosurgical specialty (b = 0.88, P < 0.0001). For exam-
ple, although the use of a protocol generally predicted
more restrictive practices, the opposite was true among
neurosurgeons (mean transfusion threshold with proto-
col, 8.43 g/dL (95% CI, 8.00 to 8.86); mean threshold
without protocol, 8.18 g/dL (95% CI, 7.81 to 8.55)). In
patients with DCI, the use of multimodal neurological
Figure 3 Relationship between respondent characteristics and transfusion thresholds. Boxplots demonstrate the median and interquartile
range. Circles represent “outside values” (± 1.5 times the interquartile range). Boxes represent “far out values” (± 3 times the interquartile range).
(A) Country. (B) Specialty. The term “intensivist” refers both to individuals who practice exclusively as neurointensivists and to multidisciplinary
intensivists who regularly care for patients with subarachnoid hemorrhage. (C) Use of multimodal neurological monitoring. (D) Use of transfusion
protocol. DCI, delayed cerebral ischemia; Hb, hemoglobin. “Grade” refers to World Federation of Neurological Surgeons classification. *P < 0.05
using the Wilcoxon rank-sum test.
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controlled trial. Boxplots demonstrate median and interquartile range. Circles represent “outside values” (± 1.5 times the interquartile range).
Boxes represent “far out values” (± 3 times the interquartile range). (A) Country. (B) Specialty. The term “intensivist” refers both to individuals
who practice exclusively as neurointensivists and to multidisciplinary intensivists who regularly care for patients with subarachnoid hemorrhage.
(C) Use of multimodal neurological monitoring. (D) Use of transfusion protocol. DCI, delayed cerebral ischemia; Hb, haemoglobin. “Grade” refers
to World Federation of Neurological Surgeons classification. *P < 0.05 using the Wilcoxon rank-sum test.
Table 2 Multivariable analysis assessing associations between respondent characteristics and transfusion thresholds in
clinical practice
a
Clinical setting value Predictors remaining in final model Estimate (b) P
WFNS grade 4 (day 3) Specialty (neurosurgery) 0.46 0.003
WFNS grade 1 (day 3) Transfusion protocol -0.42 0.0008
Transfusion protocol
b
Specialty (neurosurgery)
c
0.88 <0.0001
TCD vasospasm (day 6) Specialty (neurosurgery) 0.31 0.04
d
DCI (day 7) Multimodal neurological monitoring 0.32 0.04
aMultivariable analysis was performed using generalized linear models with stepwise backward elimination of the least significant variable where P > 0.05. Initial
models included country (United States vs. Canada), specialty (neurosurgery vs. critical care), multimodal monitoring (yes vs. no), use of a transfusion protocol
(yes vs. no) and years in practice (continuous variable). All interactions were assessed, and those for which P < 0.05 in univariate analysis were incorporated into
initial multivariable models. WFNS, World Federation of Neurological Surgeons scale; TCD, transcranial Doppler; DCI, delayed cerebral ischemia.
bNeurosurgical
specialty significantly modified practices among clinicians who use a protocol (see Results section for details);
cYears in practice significantly modified practices
among neurosurgeons (see Results section for details);
dWhite’s heteroscedasticity-specific standard error.
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more liberal transfusion threshold (b = 0.32, P = 0.04).
In the context of a randomized, controlled trial, neu-
rosurgical specialty and increased clinician seniority
were associated with less willingness to accept very
restrictive transfusion thresholds (Tables 2 and 3). In
the liberal transfusion arm, we found significant effect
measure modification between neurosurgical specialty
and years in practice. The highest Hb targets were gen-
erally found among neurosurgeons with a greater degree
of experience. For example, among neurosurgeons who
had been in practice for more than 10 years, the mean
highest acceptable Hb goal was 10.60 g/dL (95% CI,
10.13 to 11.07) compared with 10.04 g/dL (95% CI, 9.62
to 10.45) among neurosurgeons in practice for fewer
years and 10.22 g/dL (95% CI, 10.03 to 10.41) among
intensivists in practice for more than 10 years.
Clinicians using transfusion protocols were less willing
to target higher Hb goals in patients with DCI (b =
-0.35, P = 0.003). However, this effect was modified by
clinician specialty; for example, the mean highest accep-
table Hb target was 10.70 g/dL (95% CI, 10.26 to 11.15)
among neurosurgeons using a protocol, but only
10.57 g/dL (95% CI, 10.14 to 11.00) when no protocol
was used.
Discussion
Our findings describe current RBC transfusion practices
in patients with SAH at North American academic cen-
ters. We observed variations in the Hb concentrations
which trigger a decision to initiate transfusion, distribu-
ted over a numerically modest but clinically significant
r a n g eo f7t o1 1g / d L( F i g u r e1 ) .A l t h o u g hat h r e s h o l d
of 7 g/dL is widely advocated for general critical care
patients, tolerance for such a low Hb level is less com-
mon in SAH patients. The variability in clinicians’ prac-
tices provides a strong impetus for a definitive
randomized, controlled trial.
Many clinicians do not practice with a fixed Hb
threshold. Instead, the decision to initiate transfusion
varies on the basis of the clinical status of the patient.
Survey respondents were more likely to initiate transfu-
sion in patients with high-grade rather than low-grade
SAH. This practice suggests that clinicians believe ane-
mia to be potentially more harmful among patients with
a greater degree of brain injury. Clinicians are even
more likely to initiate transfusion if patients develop cer-
ebral vasospasm, especially if there is concomitant neu-
rological deterioration (that is, DCI). This observation
indicates that most clinicians do not consider marked
hemodilution to be an appropriate method of treating
vasospasm and DCI. Indeed, although hemodilution
increases CBF, this practice may compromise oxygen
delivery [18,19]. In some SAH patients, there may be
additional systemic factors (for example, neurogenic car-
diac dysfunction or known coronary artery disease)
which may influence the decision to initiate transfusion;
these factors were not incorporated into this survey.
The stated willingness of most clinicians to modify
their transfusion practices in the context of a rando-
mized, controlled trial further demonstrates equipoise.
Almost three-fourths of respondents considered it rea-
sonable to randomize a patient with grade 4 SAH to a
transfusion threshold of 7 or 7.5 g/dL. However,
Table 3 Multivariable analysis assessing associations between respondent characteristics and transfusion thresholds in
the context of a randomized, controlled trial
a
Clinical setting Predictors remaining in final model Estimate (b) P value
WFNS grade 4
(lowest acceptable Hb) Specialty (neurosurgery) 0.37 <0.0001
Years in practice 0.01 0.009
WFNS grade 4
(highest acceptable Hb) Specialty (neurosurgery)
b
Years in practice
c,d
0.03 0.01
DCI
(lowest acceptable Hb) Years in practice 0.02 0.01
DCI
(highest acceptable Hb) Transfusion protocol -0.35 0.003
Years in practice 0.02 0.007
Transfusion protocol
b
Specialty (neurosurgery)
b
0.66 0.002
aMultivariable analysis was performed using generalized linear models with stepwise backward elimination of the least significant variable where P > 0.05. Initial
models included country (United States vs. Canada), specialty (neurosurgery vs. critical care), multimodal monitoring (yes vs. no), use of a transfusion protocol
(yes vs. no) and years in practice (continuous variable). All interactions were assessed, and those for which P < 0.05 in univariate analysis were incorporated into
initial multivariable models. WFNS, World Federation of Neurological Surgeons scale; Hb, hemoglobin concentration; DCI, delayed cerebral ischemia.
bNeurosurgical specialty significantly modified practices among clinicians who use a protocol (see Results section for details);
cWhite’s heteroscedasticity-specific
standard error;
dYears in practice significantly modified practices among neurosurgeons (see Results section for details).
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when patients develop DCI. The vast majority also
thought it was acceptable to target a Hb concentration
of >10 g/dL as part of a liberal transfusion strategy.
Among patients with DCI, a notable proportion of clini-
cians were willing to target even higher Hb levels. These
findings suggest that a comparison of two fixed Hb
thresholds may not represent the most relevant
approach to study in a randomized, controlled trial.
Indeed, it has been pointed out that there may be unin-
tended harmful consequences in studies that use fixed
treatment protocols for therapies that are more often
titrated in day-to-day practice [20]. An alternative
approach is to use adaptive trial designs in which ther-
apy titration is permitted on the basis of prospective
rules. For example, the upper and lower transfusion trig-
gers could be adjusted on the basis of the presence or
absence of DCI and radiographic evidence of vasospasm.
Our findings suggest that vascular neurosurgeons are
less tolerant than intensivists regarding Hb reductions.
Neurosurgeons were also more likely to administer 2 U
rather than 1 U of RBCs when Hb levels dropped below
their usual transfusion thresholds. These findings are
consistent with a previous survey which reported that
U.S. neurosurgeons are more likely than trauma sur-
geons or intensivists to target Hb concentrations of at
least 10 g/dL in patients with severe traumatic brain
injury [21].
We identified additional factors which may influence the
transfusion decision. Although differences were small,
clinicians who reported using a transfusion protocol gen-
erally appeared to be slightly more restrictive in their use
of RBCs. This was not true for vascular neurosurgeons;
however, our data do not allow us to determine whether
this apparent discrepancy is due to variations in protocols,
lack of compliance or chance. The preferred transfusion
thresholds in a randomized trial would be higher for clini-
cians with a greater degree of seniority. The reasons for
this observation are also unclear. Possibilities could
include less familiarity with published literature advocating
restrictive transfusion strategies, increased skepticism
regarding the applicability of such studies to SAH patients
or greater reluctance to adapt practices. These observa-
tions, together with interdisciplinary and international dif-
ferences in transfusion preferences, should be taken into
consideration in the planning of future studies. This will
help maximize clinician buy-in and ensure that study
results are widely generalizable.
This survey is the first to assess how transfusion prac-
tices are influenced by advanced neurological monitor-
ing. We found that clinicians who use invasive,
multimodal neurological monitoring may be more lib-
eral in their use of transfusions, especially among
patients with DCI. To keep the survey brief, we
restricted further questioning to the use of PbtO2 probes
and microdialysis catheters (see Appendix 2 in Addi-
tional file 2). The majority of clinicians are more likely
to transfuse when PbtO2 values fall below 15 mmHg.
A considerably smaller proportion are more likely to
initiate transfusion when the PbtO2 level is 15 to
20 mmHg. It is important to point out that transfusion
is usually considered as a method to raise PbtO2 only if
other strategies (for example, optimizing cerebral perfu-
sion pressure and partial pressure of oxygen) have failed.
A definitive, “critical” PbtO2 threshold value has never
been identified with certainty. On the basis of associa-
tions with poor outcomes, levels of 10 to 20 mmHg
have been advocated both in patients with severe trau-
matic brain injury and in patients with SAH [22-24].
Evidence of ischemia found by using positron emission
tomography has been demonstrated at a PbtO2 threshold
of approximately 14 mmHg [25]. An ongoing National
Institutes of Health-sponsored phase II clinical trial in
traumatic brain injury patients uses a PbtO2 threshold of
20 mmHg to initiate therapy [26]. The clinical signifi-
cance of an elevated lactate-to-pyruvate ratio (LPR) is
less clear to clinicians; only one-third of respondents
indicated that an LPR value greater than 40 would influ-
ence them to initiate transfusion. However, experience
with microdialysis in patients with SAH is limited in
North America (Table 1). Among clinicians who report
regular use of microdialysis, a LPR threshold of about
35 to 40 appears to be considered critical. A high LPR
has been shown to be predictive of poor outcome after
SAH [27]. However, pronounced LPR elevations may
o c c u ri nt h ea b s e n c eo fi s c h e m i a[ 2 8 ]a n dm a yn o tb e
modified by the administration of RBCs [29].
Survey validity is enhanced by a high response rate. To
maximize responses, we corresponded with program
directors prior to initiation of the survey, sent three
reminder emails to potential respondents and deliberately
kept the questionnaire short. The survey was case-based,
with interactive scenarios designed to reflect typical clini-
cal practice. Our response rate (53%) is relatively consis-
tent with that of other published surveys of physicians
[30,31]. However, as with most surveys, it is impossible
for us to determine whether there were systematic differ-
ences in transfusion practices between responders and
nonresponders. In addition, there may be differences
between what clinicians perceive that they do and how
they actually practice. Because of a higher response rate,
we can be more confident of the validity of our findings
among Canadian clinicians than among U.S. clinicians.
Although our sampling frame was selected specifically
to target clinicians most influential in the care of
patients with SAH, we may not have surveyed all poten-
tial decision makers; in particular, we did not include
responses from residents or nurse practitioners. Since
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not provide a monetary (or other) incentive and chose
to perform only an Internet-based rather than a postal
questionnaire. There are some data to suggest that
response rates are higher in postal surveys [32]. On the
other hand, our response rate, especially from Canadian
intensivists and neurosurgeons, compares favorably with
what has been reported elsewhere [30-32]. Because most
respondents completed the survey anonymously, we
could not record at which particular center they work.
Thus, it is possible that our results could have been
influenced by variations in the number of responders
per center, and it is conceivable that this could have led
us to underestimate the degree of variability in transfu-
sion practices. Finally, it remains unclear to what degree
our findings reflect current practices in other regions of
the world.
Conclusions
There is widespread variation in practices regarding the
use of RBC transfusions in the management of SAH
patients at North American academic medical centers.
Equipoise is further demonstrated by the willingness of
clinicians to compare relatively divergent Hb transfusion
thresholds in the context of a randomized clinical trial.
Transfusion practices are heavily influenced by the spe-
cific dynamic clinical characteristics of patients and may
be further modified by clinician specialty, the use of
protocols and clinicians’ years in practice.
Key messages
￿ There is widespread practice variation in the use of
RBC transfusions among North American clinicians
caring for critically ill patients with aneurysmal
SAH. Most clinicians do not use an Hb transfusion
trigger of 7 g/dL and are willing to modify their
usual practices in the context of a randomized, con-
trolled trial.
￿ Clinicians target higher Hb goals among patients
with higher-grade SAH and in the presence of cere-
b r a lv a s o s p a s mo rD C I .T h u s ,c o m p a r i s o no f“fixed”
Hb thresholds applied regardless of specific clinical
circumstances may not represent the optimal
approach in future clinical trials assessing “liberal”
versus “restrictive” transfusion practices.
￿ There are significant interdisciplinary differences in
clinicians’ transfusion practices. Vascular neurosur-
geons appear to be more aggressive than intensivists
in their use of RBC transfusions. International differ-
ences between American and Canadian practices
were also observed.
￿ Most clinicians are more likely to initiate transfu-
sion in patients if PbtO2 is <15 mmHg. There is
more uncertainty when PbtO2 is 15 to 20 mmHg
and with information derived from cerebral micro-
dialysis (lactate-to-pyruvate ratio).
Additional material
Additional file 1: Appendix 1. Copy of online survey used to collect
data for this study (Canadian version).
Additional file 2: Appendix 2. Modification of transfusion practices on
the basis of information provided by PbtO2 and microdialysis (lactate-to-
pyruvate ratio) monitoring.
Abbreviations
CBF: cerebral blood flow; DCI: delayed cerebral ischemia; GCS: Glasgow
Coma Scale; Hb: hemoglobin; IQR: interquartile range; LPR: lactate-to-
pyruvate ratio; MRI: magnetic resonance imaging; PbtO2: brain tissue oxygen
tension; RBC: red blood cell; SAH: subarachnoid hemorrhage; TCD:
transcranial Doppler; WFNS: World Federation of Neurological Surgeons
score.
Author details
1Departments of Critical Care Medicine and Clinical Neurosciences, Hotchkiss
Brain Institute, Foothills Medical Center, University of Calgary, 1403 29th
Street NW, Calgary, AB T2N 2T9, Canada.
2Department of Neurology and
Neurological Surgery, Neurology/Neurosurgery Intensive Care Unit,
Washington University School of Medicine, Campus Box 8111, 660 S. Euclid
Avenue, St Louis, MO 63110, USA.
3Department of Neurology, Divisions of
Vascular Neurology and Neurocritical Care, Baylor College of Medicine, 6501
Fannin Street, MS: NB320, Houston, TX 77030, USA.
4Department of
Neurology, Feinberg School of Medicine, Northwestern University, 710 N.
Lake Shore Drive, Chicago, IL 60611, USA.
5Division of Neurosurgery,
Department of Surgery, St. Michael’s Hospital, University of Toronto, 30 Bond
Street, Toronto, ON M5B 1W8, Canada.
6Department of Neurosurgery,
University of Pennsylvania, 235 S. 8th Street, Philadelphia, PA 19106, USA.
Authors’ contributions
AHK and PL conceived, designed and carried out the survey. They were also
responsible for the analysis and interpretation of the data as well as the
drafting and revision of the manuscript. JIS, AMN and RLM assisted in
designing the survey, interpreting the data and revising the manuscript. All
authors approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 July 2010 Revised: 4 October 2010
Accepted: 18 January 2011 Published: 18 January 2011
References
1. Miller JD, Sweet RC, Narayan R, Becker DP: Early insults to the injured
brain. JAMA 1978, 240:439-442.
2. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL: The
International Cooperative Study on the Timing of Aneurysm Surgery.
Part 1: Overall management results. J Neurosurg 1990, 73:18-36.
3. Bendel P, Koivisto T, Kononen M, Hanninen T, Huarskainen H, Saari T,
Vapalahti M, Hernesniemi J, Vanninen R: MR imaging of the brain 1 year
after aneurysmal subarachnoid hemorrage: randomized study
comparing surgical with endovascular treatment. Radiology 2008,
246:543-552.
4. Kramer AH, Zygun DA: Anemia and red blood cell transfusion in
neurocritical care. Crit Care 2009, 13:R89.
5. Smith MJ, Stiefel MF, Magge S, Frangos S, Bloom S, Gracias V, Le Roux PD:
Packed red blood cell transfusion increases local cerebral oxygenation.
Crit Care Med 2005, 33:1104-1108.
6. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN: Red
blood cell transfusion increases cerebral oxygen delivery in anemic
patients with subarachnoid hemorrhage. Stroke 2009, 40:3039-3044.
Kramer et al. Critical Care 2011, 15:R30
http://ccforum.com/content/15/1/R30
Page 10 of 117. Kurtz P, Helbok R, Schmidt JM, Claassen J, Fernandez L, Morgan Stuart R,
Sander Connolly E, Lee K, Mayer S, Badjatia N: The effect of packed red
blood cell transfusion on cerebral oxygenation and metabolism after
subarachnoid hemorrhage. Critical Care 2010, 14:P341.
8. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA,
Ostapkovich N, Parra A, Connolly ES, Mayer SA: Impact of medical
complications on outcome after subarachnoid hemorrhage. Crit Care
Med 2006, 34:617-623.
9. Naidech AM, Drescher J, Ault ML, Shaibani A, Batjer HH, Alberta MJ: Higher
hemoglobin is associated with less cerebral infarction, poor outcome,
and death after subarachnoid hemorrhage. Neurosurgery 2006, 59:775-779.
10. Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B:
Relationship between hemoglobin concentrations and outcomes across
subgroups of patients with aneurysmal subarachnoid hemorrhage.
Neurocrit Care 2009, 10:20-27.
11. Kahn JM, Caldwell EC, Deem S, Newell DW, Heckbert SR, Rubenfeld GD:
Acute lung injury in patients with subarachnoid hemorrhage: incidence,
risk factors, and outcome. Crit Care Med 2006, 34:196-202.
12. Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck TP:
Complications associated with anemia and blood transfusion in patients
with aneurysmal subarachnoid hemorrhage. Crit Care Med 2008,
36:2070-2075.
13. Levine J, Kofke A, Cen L, Chen Z, Faerber J, Ellioo JP, Winn HR, Le Roux P:
Red blood cell transfusion is associated with infection and extracerebral
complications after subarachnoid hemorrhage. Neurosurgery 2010,
66:312-318.
14. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G,
Tweeddale M, Schweitzer I, Yetisir E: A multicenter, randomized,
controlled clinical trial of transfusion requirements in critical care.
Transfusion Requirements in Critical Care Investigators, Canadian Critical
Care Trials Group. N Engl J Med 1999, 340:409-417.
15. Lacroix J, Hébert PC, Hutchson JS, Hume HA, Tucci M, Ducruet T, Gauvin F,
Collet JP, Toledano BJ, Robillard P, Joffe A, Biarent D, Meert K, Peters MJ,
TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute
Lung Injury and Sepsis Investigators Network: Transfusion strategies for
patients in pediatric intensive care units. N Engl J Med 2007,
356:1609-1619.
16. Stevens RD, Naval NS, Mirski MA, Citerio G, Andrews PJ: Intensive care of
aneurysmal subarachnoid hemorrhage: an international survey. Intensive
Care Med 2009, 35:1556-1566.
17. SurveyMonkey. [http://www.surveymonkey.com/?cmpid=eng:us:ps:
google&gclid=CP2cqqeM06YCFYHc4AodrjwfIQ].
18. Ekelund A, Reinstrup P, Ryding E, Andersson AM, Molund T, Kristiansson KA,
Romner B, Brandt L, Saveland H: Effects of iso- and hyeprvolemic
hemodilution on regional cerebral blood flow and oxygen delivery for
patients with vasospasm after aneurysmal subarachnoid hemorrhage.
Acta Neurochir (Wien) 2002, 144:703-713.
19. Muench E, Horn P, Bauhuf C, Roth H, Philipps M, Hermann P, Quintel M,
Schmiedek P, Vajkoczy P: Effects of hypervolemia and hypertension on
regional cerebral blood flow, intracranial pressure, and brain tissue
oxygenation after subarachnoid hemorrhage. Crit Care Med 2007,
35:1844-1851.
20. Deans KJ, Minneci PC, Suffredini AF, Danner RL, Hoffman WD, Ciu X,
Klein HG, Schechter AN, Banks SM, Eichacker PQ, Natanson C:
Randomization in clinical trials of titrated therapies: unintended
consequences of using fixed treatment protocols. Crit Care Med 2007,
35:1509-1516.
21. Sena MJ, Rivers RM, Muizelaar JP, Battistella FD, Utter GH: Transfusion
practices for acute traumatic brain injury: a survey of physicians at U.S.
trauma centers. Intensive Care Med 2009, 35:480-488.
22. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS: Relationship
of brain tissue PO2 to outcome after severe head injury. Crit Care Med
1998, 26:1576-1581.
23. Van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ, Suazo JA,
Hogesteeger C, Jansen WJ, Kloos LM, Vermeulen J, Maas AI: Brain oxygen
tension in severe head injury. Neurosurgery 2000, 46:868-876.
24. Ramakrishna R, Stiefel M, Udoetuk J, Spiotta A, Levine JM, Kofke WA,
Zager E, Yang W, LeRoux P: Brain oxygen tension and outcome in
patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2008,
109:1075-1082.
25. Johnston AJ, Steiner LA, Coles JP, Chatfield DA, Fryer TD, Smielwski P,
Hutchinson PJ, O’Connell MT, Al-Rawi PG, Aigbirihio FI, Clark JC, Pickard JD,
Gupta AK, Menon DK: Effect of cerebral perfusion pressure augmentation
on regional oxygenation and metabolism after head injury. Crit Care Med
2005, 33:189-195.
26. Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI) (BOOST
2). [http://www.clinicaltrials.gov/ct2/show/NCT00974259?term=brain
+oxygen&rank=3].
27. Sarrafzadeh A, Haux D, Kuchler I, Lanksch WR, Unterberg AW: Poor-grade
aneurismal subarachnoid hemorrhage: relationship of cerebral
metabolism to outcome. J Neurosurg 2004, 100:400-406.
28. Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC,
McArthur DL, Hovda DA: Metabolic crisis without brain ischemia is
common after traumatic brain injury: a combined microdialysis and
positron emission tomography study. J Cereb Blood Flow Metab 2005,
25:763-774.
29. Zygun DA, Nortje J, Hutchinson PJ, Timofeev I, Menon DK, Gupta AK: The
effect of red blood cell transfusion on cerebral oxygenation and
metabolism after severe traumatic brain injury. Crit Care Med 2009,
37:1074-1078.
30. Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, Cook DJ,
ACCADEMY Group: A guide for the design and conduct of self-
administered surveys of clinicians. CMAJ 2008, 179:245-252.
31. Cummings SM, Savitz LA, Konrad TR: Reported response rates to mailed
physician questionnaires. Health Serv Res 2001, 35:1347-1355.
32. Leece P, Bhandari M, Sprague S, Swiontkowski MF, Schemitsch EH,
Tornetta P, Devereaux PJ, Guyatt GH: Internet versus mailed
questionnaires: a randomized comparison (2). J Med Internet Res 2004, 6:
e39.
doi:10.1186/cc9977
Cite this article as: Kramer et al.: Red blood cell transfusion in patients
with subarachnoid hemorrhage: a multidisciplinary North American
survey. Critical Care 2011 15:R30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kramer et al. Critical Care 2011, 15:R30
http://ccforum.com/content/15/1/R30
Page 11 of 11